BioMarin Pharmaceutical Inc. Initiates Phase 3 Trial for PEG-PAL for the Treatment of PKU
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU).
Help employers find you! Check out all the jobs and post your resume.
SAN RAFAEL, Calif., June 5, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU).
Help employers find you! Check out all the jobs and post your resume.